Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes
Elisabetta Sauta(Humanitas University), Matteo Giovanni Della Porta(Humanitas University), Pierre Fenaux(Hôpital Avicenne), Lorenzo Dall’Olio, Victor Savevski(Humanitas University), Alessia Campagna(Humanitas University), Matteo Zampini(Humanitas University), Gastone Castellani(University of Bologna), Erica Travaglino(Policlinico San Matteo Fondazione), Anne Sophie Kubasch(Leukemia and Lymphoma Society), Marilena Bicchieri(Humanitas University), Claudia Sala, Daniele Dall’Olio, Torsten Haferlach(Munich Leukemia Laboratory (Germany)), Cristina Astrid Tentori(IRCCS Humanitas Research Hospital), Shahram Kordasti(Guy's Hospital), Gabriele Todisco(Humanitas University), María Díez‐Campelo(Complejo Hospitalario de Salamanca), Amer M. Zeidan(Yale Cancer Center), Lin‐Pierre Zhao, Marta Ubezio(Humanitas University), Uwe Platzbecker(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ettore Mosca(Institute of Biomedical Technologies), Giulia Maggioni(Humanitas University), Luca Lanino(Humanitas University), Valeria Santini(University of Florence), Gianluca Asti(IRCCS Humanitas Research Hospital), Elena Riva(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Saverio D’Amico(Humanitas University)
Cited by 2
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k